[go: up one dir, main page]

MX2021011008A - Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a. - Google Patents

Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.

Info

Publication number
MX2021011008A
MX2021011008A MX2021011008A MX2021011008A MX2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A MX 2021011008 A MX2021011008 A MX 2021011008A
Authority
MX
Mexico
Prior art keywords
receptor
piperidinyl
fusioned
modulars
piperidinyl compounds
Prior art date
Application number
MX2021011008A
Other languages
English (en)
Inventor
Yong Li
Niels Christoph Riedemann
Renfeng Guo
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of MX2021011008A publication Critical patent/MX2021011008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención actual se refiere a piperidinilo bicíclico de piperidinilo fusionado, piperidinilo sustituido en meta y sus compuestos relacionados que modulan las actividades del receptor C5a de mamífero que se unen directamente al receptor C5a. La invención también se refiere a composiciones farmacéuticas que contienen tales compuestos y su uso en el tratamiento de una enfermedad o trastorno que implica la activación patógena de los receptores C5a.
MX2021011008A 2019-03-11 2020-02-07 Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a. MX2021011008A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962816726P 2019-03-11 2019-03-11
EP19177349 2019-05-29
US201962873612P 2019-07-12 2019-07-12
PCT/EP2020/053171 WO2020182384A1 (en) 2019-03-11 2020-02-07 Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor

Publications (1)

Publication Number Publication Date
MX2021011008A true MX2021011008A (es) 2021-10-13

Family

ID=69526272

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021011008A MX2021011008A (es) 2019-03-11 2020-02-07 Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
MX2024014462A MX2024014462A (es) 2019-03-11 2021-09-10 Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024014462A MX2024014462A (es) 2019-03-11 2021-09-10 Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a

Country Status (15)

Country Link
US (3) US11149009B2 (es)
EP (1) EP3938351A1 (es)
JP (1) JP7360745B2 (es)
KR (1) KR102702654B1 (es)
CN (2) CN113784955B (es)
AU (1) AU2020234859B2 (es)
BR (1) BR112021017756A2 (es)
CA (1) CA3129019A1 (es)
CL (1) CL2021002357A1 (es)
IL (2) IL285630A (es)
MX (2) MX2021011008A (es)
PE (1) PE20220167A1 (es)
PH (1) PH12021552171A1 (es)
SG (1) SG11202108957RA (es)
WO (1) WO2020182384A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
CN114641288A (zh) 2019-11-08 2022-06-17 凯莫森特里克斯股份有限公司 补体成分C5a受体的无定形形式
CN118908879A (zh) * 2019-11-08 2024-11-08 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
MX2023001504A (es) * 2020-08-07 2023-04-27 Kira Pharmaceuticals Suzhou Ltd Compuestos como inhibidores del receptor del componente complemento 5a (c5ar).
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
WO2024245527A1 (en) 2023-05-26 2024-12-05 Inflarx Gmbh Treatment of pneumonia and ards with inhibitors of c5a and il-6 activity
WO2025037010A1 (en) 2023-08-16 2025-02-20 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
WO2007051062A2 (en) * 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
KR102767008B1 (ko) 2016-01-14 2025-02-11 케모센트릭스, 인크. C3 사구체병증을 치료하는 방법
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
CN108727355A (zh) 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108440514A (zh) 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108440513A (zh) 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108727354A (zh) 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108558844A (zh) 2018-05-16 2018-09-21 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
US10889571B2 (en) 2018-09-18 2021-01-12 Terns, Inc. Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias
UY38423A (es) 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
GB201907616D0 (en) 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases

Also Published As

Publication number Publication date
US20200290969A1 (en) 2020-09-17
CN113784955A (zh) 2021-12-10
KR20210137157A (ko) 2021-11-17
CA3129019A1 (en) 2020-09-17
JP2022524544A (ja) 2022-05-06
AU2020234859A1 (en) 2021-09-16
IL312955B1 (en) 2026-01-01
JP7360745B2 (ja) 2023-10-13
CL2021002357A1 (es) 2022-04-22
AU2020234859B2 (en) 2025-03-13
US20240300898A1 (en) 2024-09-12
WO2020182384A1 (en) 2020-09-17
PE20220167A1 (es) 2022-01-28
NZ779253A (en) 2024-09-27
US11999698B2 (en) 2024-06-04
KR102702654B1 (ko) 2024-09-04
SG11202108957RA (en) 2021-09-29
IL312955A (en) 2024-07-01
PH12021552171A1 (en) 2022-09-12
MX2024014462A (es) 2025-01-09
BR112021017756A2 (pt) 2021-11-16
CN113784955B (zh) 2025-02-14
IL285630A (en) 2021-09-30
US11149009B2 (en) 2021-10-19
CN119874606A (zh) 2025-04-25
EP3938351A1 (en) 2022-01-19
US20210403433A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MX2021011008A (es) Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
CL2022001271A1 (es) Agonista del receptor glp-1 y uso de este
CY1123226T1 (el) Ενωσεις 4,6-διαμινο-πυριδο[3,2-d]πυριμιδινης και χρηση αυτων ως ρυθμιστες toll-τυπου υποδοχεων
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2016002348A1 (es) Agonistas del receptor muscarínico
MX2017014621A (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma.
CO2017012545A2 (es) Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ)
MX391031B (es) Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa.
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
MX2017006448A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139).
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CL2020001140A1 (es) Compuestos espirocíclicos como moduladores del receptor farnesoide x.
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
CL2015003470A1 (es) Moduladores del receptor cxcr7.
EA201891472A1 (ru) Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
MX2016010529A (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
CL2017002405A1 (es) Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr.
CL2016002085A1 (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina.
CL2009001282A1 (es) Compuestos derivados de pirrolidin amidas sustituidas, moduladores del receptor de histamina h3; composicion farmaceutica que los contiene; y su uso para el tratamiento de enfermedades tales como demencia, alzheimer, disfuncion cognitiva, trastorno de la memoria, trastorno de aprendizaje, deficit atencional, entre otras.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa